Jeremy A. Mazurek
University of Pennsylvania
95 Papers
116 Citations
Jeremy A. Mazurek is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Pulmonary hypertension. The author has an hindex of 13, co-authored 68 publications. Previous affiliations of Jeremy A. Mazurek include Hospital of the University of Pennsylvania.
Chat about Author
Papers
Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
Yuchi Han,Paul R. Forfia,Anjali Vaidya,Jeremy A. Mazurek,Myung H. Park,Gautam V. Ramani,Stephen Y. Chan,Aaron B. Waxman +7 more
- 01 Feb 2018
TL;DR: This study is a longitudinal, randomised, double-blind, placebo-controlled, multicentre proof-of-concept study in 24 subjects with pulmonary hypertension and RV dysfunction treated with ranolazine over 6 months, and the primary outcome is change in RVEF.
14
Pulmonary Hypertension Due to Left Ventricular Cardiomyopathy: Is it the Result or Cause of Disease Progression?
TL;DR: Clinicians and researchers should take note of the importance of PH-LHD and RV dysfunction to appropriately risk stratify patients and develop therapies for the condition.
14
Pulmonary Hypertension in Heart Failure Patients
Sriram D. Rao,Srinath Adusumalli,Jeremy A. Mazurek +2 more
- 12 Aug 2019
TL;DR: The authors examine recent changes to the definition of PH in the setting of left heart disease (PH-LHD), and discuss its epidemiology, pathophysiology and prognosis.
12
Relaxin levels in pulmonary hypertension: a comparison between pulmonary arterial hypertension and diastolic heart failure-induced pulmonary hypertension.
TL;DR: This research presents a novel and scalable approach called “SmartCardiology” that allows for real-time assessment of the fluid interior of the heart during surgery and its role in protecting against ACEs.
12
BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension
Breanne E. McCarthy,Robyn L. McClelland,Dina Appleby,Jude Moutchia,Jasleen Minhas,Jeff Min,Jeremy A. Mazurek,K. Akaya Smith,Jason S. Fritz,Steven C. Pugliese,Ryan J. Urbanowicz,John H. Holmes,Harold I. Palevsky,Steven M. Kawut,Nadine Al-Naamani +14 more
TL;DR: In this article , a meta-analysis was conducted of phase III, randomized, placebo-controlled trials of treatments for pulmonary arterial hypertension submitted for approval to the U.S. Food and Drug Administration from 2000 to 2015.
11